

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, OR IN ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL, SUBJECT TO LEGAL RESTRICTIONS OR WOULD REQUIRE REGISTRATION OR OTHER MEASURES.

Nanologica Publishes supplementary Prospectus in Connection with Rights Issue

Nanologica AB (publ) ("Nanologica" or the "Company") publishes a supplement (the "Supplementary Prospectus") to the prospectus approved by the Swedish Financial Supervisory Authority and published on October 26, 2024 (the "Prospectus") regarding the ongoing rights issue (the "Rights Issue"). The Supplement Prospectus is part of and should be read together with the Prospectus.

The Supplementary Prospectus has been prepared due to the fact that the Company, following the publication of the Prospectus, through a press release on October 4, 2024 announced that the Company had received an order for its silica-based purification media NLAB Saga® from a customer in China at a value of SEK 1.9 million. Considering the size of the order, in relation to the Company's turnover, the Company believes that the order is a circumstance that may affect the assessment of the offering in the Prospectus. The press release has been published in its entirety on the Company's website www.nanologica.com.

The Supplementary Prospectus which today October 8, 2024 has been approved by the Swedish Financial Supervisory Authority, forms part of and should be read together with the Prospectus. The Prospectus and the Supplementary Prospectus are available on the Company's website (www.nanologica.com), Bergs Securities' website (www.bergssecurities.se), and the Swedish Financial Supervisory Authority's website (www.fi.se).

For complete terms and conditions and other information about the Rights Issue, please refer to the Prospectus and the Supplementary Prospectus.

Advisors

Nanologica has engaged Redeye AB as Joint Bookrunner, Bergs Securities AB as Joint Bookrunner and issuing agent, and Advokatfirman Lindahl KB as legal advisor in connection with the Rights Issue.

For further information, please contact

Johanna Johansson
Director IR, Communications and Marketing
johanna.johansson@nanologica.com
+46 72 211 21 90

About Nanologica AB (publ)

Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica's products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company's mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica's share (NICA) is listed for trading on Nasdaq Stockholm Main Market. For further information, please visit www.nanologica.com.

Attachments

[Nanologica Publishes supplementary Prospectus in Connection with Rights Issue](#)